EntryPoint Capital’s BioNTech BNTX Stock Holding History

EntryPoint Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-265	Closed	-$24.4K	–	945
2024 Q1	$24.4K	Sell	265 -55	-17%	-$5.27K	0.02%	1029
2023 Q4	$33.8K	Buy	+320	New	+$32.2K	0.03%	885

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EntryPoint Capital's BNTX Position: Q2 2024 in Review

EntryPoint Capital sold out of BioNTech (BNTX) in Q2 2024, closing a stake of 265 shares — an estimated $24.4K sold.

EntryPoint Capital first reported a position in BNTX in Q4 2023 and held it in 2 quarters. The position peaked at $33.8K in Q4 2023. 286 funds tracked by Wall St. Rank hold BNTX as of Q2 2024.

EntryPoint Capital reported no remaining BioNTech position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 265 BioNTech shares in Q2 2024, an estimated $24.4K.
EntryPoint Capital first reported a position in BioNTech in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's BioNTech position peaked at $33.8K in Q4 2023.
286 funds tracked by Wall St. Rank held BioNTech as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.